Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Immunai will support BMS’s clinical development efforts by applying its AI-powered operating system, AMICA-OS.
January 15, 2026
By: Charlie Sternberg
Immunai, an AI biotech company specializing in mapping the human immune system, has announced a strategic collaboration with Bristol Myers Squibb Company (BMS), under which Immunai will support BMS’s clinical development efforts by applying its AI-powered operating system, AMICA-OS, to gain deeper insight into patient immune responses and inform clinical decision-making.
The collaboration will leverage Immunai’s immune system AI models and infrastructure within AMICA-OS to analyze high-dimensional immune data from clinical studies. The goal is to improve understanding of patient biology and variability in response to therapy, supporting key clinical development activities including immune-driven mechanisms of action, patient stratification, biomarker discovery, and data-informed decision-making.
“Understanding the immune system at the level required to guide clinical development remains one of the most complex challenges in drug development,” said Noam Solomon, Ph.D., CEO of Immunai. “Through our collaboration with BMS, we will apply AMICA-OS to translate complex immune data into actionable insights that can support clinical decision-making and ultimately help advance better therapies for patients.”
“At Bristol Myers Squibb, we are focused on leveraging innovative approaches that deepen our understanding of patient biology and treatment response,” said Bryan Campbell, Senior Vice President, Head of Program Leadership, Hematology, Oncology, Cell Therapy at Bristol Myers Squibb. “Our collaboration with Immunai will enable the use of advanced AI technologies to generate meaningful immune insights from clinical data, supporting our efforts to advance the development of transformative medicines.”
The collaboration has the potential to expand across additional programs as the companies continue to explore the application of Immunai’s AMICA-OS to support immune-driven clinical development.
Immunai recently joined forces with AstraZeneca for the development of a target for inflammatory bowel disease (IBD).
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
